HLB Panajin will introduce its proprietary peptide nucleic acid (PNA) technology at the upcoming Oligonucleotides & Peptides Xchange–San Francisco 2026 conference in the United States.
The company announced on August 12 that it will deliver the opening keynote address at the event, scheduled for September in San Francisco.
The presentation is titled "The Overlooked Oligo: Why PNA Deserves a Closer Look in Your Pipeline." HLB Panajin plans to highlight the technical strengths of PNA and its potential applications in drug development.
This conference will gather experts and decision-makers from global pharmaceutical and biotech companies to discuss the latest technologies and business collaboration opportunities in the fields of oligonucleotides and peptide therapeutics.
During the presentation, HLB Panajin will showcase the differentiated technical advantages of PNA compared to traditional oligonucleotides, as well as its applications in various fields, including cell and gene therapies (CGT), and outline its potential as a drug development platform.
This presentation has been organized in collaboration with ChemGenes, HLB Panajin's U.S. PNA distribution partner. The company aims to expand its collaborations with local research institutions and pharmaceutical and biotech companies, strengthening its global PNA business.
Jang In-geun, CEO of HLB Panajin, stated, "PNA is a material with significant potential for various drug development fields due to its high binding affinity and stability. Through this presentation, we aim to raise awareness of PNA's competitiveness among global researchers and pharmaceutical and biotech companies, and to expand research and development collaborations and business opportunities."
Meanwhile, HLB Panajin supplies PNA-based research and diagnostic materials and reagents to over 50 countries worldwide, including the United States, Europe, Asia, the Middle East, and Oceania.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.